Milestone Pharmaceuticals Inc. Stock-Based Compensation
Milestone Pharmaceuticals Inc. (MIST) reported Stock-Based Compensation of $2.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- Milestone Pharmaceuticals Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.34M, a 2.29% increase year-over-year.
- Milestone Pharmaceuticals Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.28M, a 5.11% decline year-over-year.
- Milestone Pharmaceuticals Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.55M, a 140.98% increase year-over-year.
- Milestone Pharmaceuticals Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.25M, a 10.65% decline year-over-year.
- Milestone Pharmaceuticals Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $7.46M, a 29.17% increase from fiscal 2024.
- Milestone Pharmaceuticals Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $5.78M, a 39.42% decline from fiscal 2023.
- Milestone Pharmaceuticals Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $9.53M, a 5.37% increase from fiscal 2022.
- Milestone Pharmaceuticals Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $9.05M, a 24.30% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.62M 10-Q · filed 2026-08-12 | $6.17M derived: sum of 3 quarters · filed 2026-08-12 | $7.42M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.28M 10-Q · filed 2026-05-13 | $4.83M derived: sum of 2 quarters · filed 2026-05-13 | $6.08M derived: sum of 3 quarters · filed 2026-05-13 | $7.39M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $3.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $4.80M derived: sum of 2 quarters · filed 2026-03-20 | $6.11M derived: sum of 3 quarters · filed 2026-08-12 | $7.46M 10-K · filed 2026-03-20 |
| 2025-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.56M derived: sum of 2 quarters · filed 2026-08-12 | $3.91M 10-Q · filed 2025-11-12 | $5.38M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.66M 10-Q · filed 2026-08-12 | $4.13M derived: sum of 3 quarters · filed 2026-08-12 | $5.53M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.35M 10-Q · filed 2026-05-13 | $2.83M derived: sum of 2 quarters · filed 2026-05-13 | $4.22M derived: sum of 3 quarters · filed 2026-05-13 | $5.62M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $2.87M derived: sum of 2 quarters · filed 2026-03-20 | $4.26M derived: sum of 3 quarters · filed 2026-03-20 | $5.78M 10-K · filed 2026-03-20 |
| 2024-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.79M derived: sum of 2 quarters · filed 2025-11-12 | $4.30M 10-Q · filed 2025-11-12 | $6.18M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.90M 10-Q · filed 2025-08-12 | $4.78M derived: sum of 3 quarters · filed 2025-08-12 | $7.65M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.51M 10-Q · filed 2025-05-14 | $3.39M derived: sum of 2 quarters · filed 2025-05-14 | $6.26M derived: sum of 3 quarters · filed 2025-05-14 | $8.75M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $4.75M derived: sum of 2 quarters · filed 2025-03-13 | $7.24M derived: sum of 3 quarters · filed 2025-03-13 | $9.53M 10-K · filed 2025-03-13 |
| 2023-09-30 | $2.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $5.36M derived: sum of 2 quarters · filed 2024-11-12 | $7.66M 10-Q · filed 2024-11-12 | $9.80M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $2.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.79M 10-Q · filed 2024-08-08 | $6.93M derived: sum of 3 quarters · filed 2024-08-08 | $9.31M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.29M 10-Q · filed 2024-05-13 | $4.44M derived: sum of 2 quarters · filed 2024-05-13 | $6.82M derived: sum of 3 quarters · filed 2024-05-13 | $9.23M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $4.52M derived: sum of 2 quarters · filed 2024-03-21 | $6.93M derived: sum of 3 quarters · filed 2024-03-21 | $9.05M 10-K · filed 2024-03-21 |
| 2022-09-30 | $2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $4.79M derived: sum of 2 quarters · filed 2023-11-13 | $6.91M 10-Q · filed 2023-11-13 | $8.88M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $2.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $4.53M 10-Q · filed 2023-08-10 | $6.50M derived: sum of 3 quarters · filed 2023-08-10 | $8.52M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $2.11M 10-Q · filed 2023-05-11 | $4.09M derived: sum of 2 quarters · filed 2023-05-11 | $6.11M derived: sum of 3 quarters · filed 2023-05-11 | $8.03M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $4.00M derived: sum of 2 quarters · filed 2023-03-29 | $5.91M derived: sum of 3 quarters · filed 2023-03-29 | $7.28M 10-K · filed 2023-03-29 |
| 2021-09-30 | $2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.94M derived: sum of 2 quarters · filed 2022-11-10 | $5.30M 10-Q · filed 2022-11-10 | $6.73M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $3.28M 10-Q · filed 2022-08-10 | $4.71M derived: sum of 3 quarters · filed 2022-08-10 | $6.05M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $1.37M 10-Q · filed 2022-05-12 | $2.80M derived: sum of 2 quarters · filed 2022-05-12 | $4.14M derived: sum of 3 quarters · filed 2022-05-12 | $5.33M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $2.77M derived: sum of 2 quarters · filed 2022-03-24 | $3.96M derived: sum of 3 quarters · filed 2022-03-24 | $4.95M 10-K · filed 2022-03-24 |
| 2020-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $2.53M derived: sum of 2 quarters · filed 2021-11-12 | $3.52M 10-Q · filed 2021-11-12 | $3.87M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $2.17M 10-Q · filed 2021-08-11 | $2.53M derived: sum of 3 quarters · filed 2021-08-11 | $2.88M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $981.00K 10-Q · filed 2021-05-17 | $1.33M derived: sum of 2 quarters · filed 2021-05-17 | $1.69M derived: sum of 3 quarters · filed 2021-05-17 | $1.96M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $354.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $704.00K derived: sum of 2 quarters · filed 2021-03-29 | $980.00K derived: sum of 3 quarters · filed 2021-03-29 | $1.19M 10-K · filed 2021-03-29 |
| 2019-09-30 | $350.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $626.00K derived: sum of 2 quarters · filed 2020-11-13 | $837.00K 10-Q · filed 2020-11-13 | $1.18M derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | $276.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $487.00K 10-Q · filed 2020-08-12 | $831.00K derived: sum of 3 quarters · filed 2020-10-23 | $916.00K derived: sum of 4 quarters · filed 2020-10-23 |
| 2019-03-31 | $211.00K 10-Q · filed 2020-05-14 | $555.00K derived: sum of 2 quarters · filed 2020-10-23 | $640.00K derived: sum of 3 quarters · filed 2020-10-23 | $719.00K derived: sum of 4 quarters · filed 2020-10-23 |
| 2018-12-31 | $344.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-10-23 | $429.00K derived: sum of 2 quarters · filed 2020-10-23 | $508.00K derived: sum of 3 quarters · filed 2020-10-23 | $633.00K 10-K/A · filed 2020-10-23 |
| 2018-09-30 | $85.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $164.00K derived: sum of 2 quarters · filed 2019-11-13 | $289.00K 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $204.00K 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | $125.00K 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |